Suppr超能文献

ZMIZ1 和 NOTCH1 通路在急性 T 淋巴细胞白血病中在 C-MYC 处汇聚。

Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias.

机构信息

Division of Hematology-Oncology, Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

出版信息

Cancer Res. 2013 Jan 15;73(2):930-41. doi: 10.1158/0008-5472.CAN-12-1389. Epub 2012 Nov 16.

Abstract

Activating NOTCH1 mutations are found in 50% to 60% of human T-cell acute lymphoblastic leukemia (T-ALL) samples. In mouse models, these mutations generally fail to induce leukemia. This observation suggests that NOTCH1 activation must collaborate with other genetic events. Mutagenesis screens previously implicated ZMIZ1 as a possible NOTCH1 collaborator in leukemia. ZMIZ1 is a transcriptional coactivator of the protein inhibitor of activated STAT (PIAS)-like family. Its role in oncogenesis is unknown. Here, we show that activated NOTCH1 and ZMIZ1 collaborate to induce T-ALL in mice. ZMIZ1 and activated NOTCH1 are coexpressed in a subset of human T-ALL patients and cell lines. ZMIZ1 inhibition slowed growth and sensitized leukemic cells to corticosteroids and NOTCH inhibitors. Gene expression profiling identified C-MYC, but not other NOTCH-regulated genes, as an essential downstream target of ZMIZ1. ZMIZ1 functionally interacts with NOTCH1 to promote C-MYC transcription and activity. The mechanism does not involve the NOTCH pathway and appears to be indirect and mediated independently of canonical PIAS functions through a novel N-terminal domain. Our study shows the importance of identifying genetic collaborations between parallel leukemic pathways that may be therapeutically targeted. They also raise new inquiries into potential NOTCH-ZMIZ1 collaboration in a variety of C-MYC-driven cancers.

摘要

NOTCH1 激活突变存在于 50%至 60%的人类 T 细胞急性淋巴细胞白血病 (T-ALL) 样本中。在小鼠模型中,这些突变通常不能诱导白血病。这一观察结果表明,NOTCH1 的激活必须与其他遗传事件协同作用。先前的诱变筛选将 ZMIZ1 鉴定为白血病中 NOTCH1 的可能协同因子。ZMIZ1 是激活 STAT 蛋白抑制剂 (PIAS)-样家族的转录共激活因子。其在肿瘤发生中的作用尚不清楚。在这里,我们表明激活的 NOTCH1 和 ZMIZ1 协同诱导小鼠发生 T-ALL。ZMIZ1 和激活的 NOTCH1 在一部分人类 T-ALL 患者和细胞系中共同表达。ZMIZ1 抑制减缓了生长速度,并使白血病细胞对皮质类固醇和 NOTCH 抑制剂敏感。基因表达谱分析确定 C-MYC 是 ZMIZ1 的一个必需下游靶点,但不是其他 NOTCH 调节的基因。ZMIZ1 与 NOTCH1 功能相互作用,促进 C-MYC 转录和活性。该机制不涉及 NOTCH 途径,并且似乎是间接的,通过 novel N-terminal 结构域独立于经典的 PIAS 功能介导。我们的研究表明,确定可能成为治疗靶点的平行白血病途径之间的遗传协同作用非常重要。它们还引发了对各种 C-MYC 驱动的癌症中潜在的 NOTCH-ZMIZ1 协同作用的新探究。

相似文献

1
Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias.
Cancer Res. 2013 Jan 15;73(2):930-41. doi: 10.1158/0008-5472.CAN-12-1389. Epub 2012 Nov 16.
2
The PIAS-like Coactivator Zmiz1 Is a Direct and Selective Cofactor of Notch1 in T Cell Development and Leukemia.
Immunity. 2015 Nov 17;43(5):870-83. doi: 10.1016/j.immuni.2015.10.007. Epub 2015 Oct 27.
3
Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell development.
Blood. 2018 Sep 20;132(12):1279-1292. doi: 10.1182/blood-2018-02-835850. Epub 2018 Aug 3.
4
MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.
Sci Signal. 2017 Nov 14;10(505):eaam6846. doi: 10.1126/scisignal.aam6846.
6
High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.
Blood. 2016 Nov 3;128(18):2229-2240. doi: 10.1182/blood-2016-01-692855. Epub 2016 Sep 26.
7
The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Haematologica. 2014 Dec;99(12):1808-16. doi: 10.3324/haematol.2014.115683. Epub 2014 Oct 24.
8
The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia.
PLoS One. 2017 Oct 12;12(10):e0185762. doi: 10.1371/journal.pone.0185762. eCollection 2017.
9
A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.
Nat Med. 2014 Oct;20(10):1130-7. doi: 10.1038/nm.3665. Epub 2014 Sep 7.
10
DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia.
Oncogene. 2013 Oct;32(40):4845-53. doi: 10.1038/onc.2012.482. Epub 2012 Oct 29.

引用本文的文献

1
Association of genetic variants, protein domains, and phenotypes in the ZMIZ1 syndromic neurodevelopmental disorder.
Front Neurosci. 2025 Jun 3;19:1605762. doi: 10.3389/fnins.2025.1605762. eCollection 2025.
2
Native stem cell transcriptional circuits define cardinal features of high-risk leukemia.
J Exp Med. 2025 Apr 7;222(4). doi: 10.1084/jem.20231349. Epub 2025 Feb 19.
3
Targeting the ZMIZ1-Notch1 signaling axis for the treatment of tongue squamous cell carcinoma.
Sci Rep. 2024 Jun 12;14(1):13577. doi: 10.1038/s41598-024-59882-y.
4
Zmiz1 is a novel regulator of lymphatic endothelial cell gene expression and function.
PLoS One. 2024 May 8;19(5):e0302926. doi: 10.1371/journal.pone.0302926. eCollection 2024.
5
Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability.
Front Psychiatry. 2024 Apr 15;15:1375492. doi: 10.3389/fpsyt.2024.1375492. eCollection 2024.
6
Decreased ZMIZ1 suppresses melanogenesis in vitiligo by regulating mTOR/AKT/GSK-3β-mediated glucose uptake.
In Vitro Cell Dev Biol Anim. 2024 Jan;60(1):67-79. doi: 10.1007/s11626-023-00837-4. Epub 2023 Dec 20.
8
Dissecting the pathogenic effects of smoking and its hallmarks in blood DNA methylation on colorectal cancer risk.
Br J Cancer. 2023 Oct;129(8):1306-1313. doi: 10.1038/s41416-023-02397-6. Epub 2023 Aug 22.
9
Zmiz1 is a novel regulator of lymphatic endothelial cell gene expression and function.
bioRxiv. 2023 Jul 22:2023.07.22.550165. doi: 10.1101/2023.07.22.550165.
10
Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL).
Cancers (Basel). 2022 Sep 1;14(17):4290. doi: 10.3390/cancers14174290.

本文引用的文献

1
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
Nature. 2012 Jan 11;481(7380):157-63. doi: 10.1038/nature10725.
2
Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think.
J Exp Med. 2011 Sep 26;208(10):1931-5. doi: 10.1084/jem.20111855.
3
Cell of origin strongly influences genetic selection in a mouse model of T-ALL.
Blood. 2011 Oct 27;118(17):4646-56. doi: 10.1182/blood-2011-03-343947. Epub 2011 Aug 9.
5
Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia.
Blood. 2011 Mar 10;117(10):2901-9. doi: 10.1182/blood-2010-05-286351. Epub 2011 Jan 7.
7
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
Blood. 2010 Feb 11;115(6):1175-84. doi: 10.1182/blood-2009-04-214718. Epub 2009 Dec 11.
8
Genetic inactivation of Ikaros is a rare event in human T-ALL.
Leuk Res. 2010 Apr;34(4):426-9. doi: 10.1016/j.leukres.2009.09.012. Epub 2009 Sep 30.
9
The canonical Notch signaling pathway: unfolding the activation mechanism.
Cell. 2009 Apr 17;137(2):216-33. doi: 10.1016/j.cell.2009.03.045.
10
NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia.
Leukemia. 2009 Aug;23(8):1374-7. doi: 10.1038/leu.2009.75. Epub 2009 Apr 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验